Allegro Diagnostics is set to present results of its BronchoGen genomic test, from Airway Epithelium Gene Expression In the Diagnosis of Lung Cancer (AEGIS) clinical trials, in a late-breaking abstract session at CHEST to be held on 23 October 2012.
The prospective, multi-center AEGIS trials are designed to assess the prediction accuracy of the BronchoGen genomic test compared to and in combination with bronchoscopy.
By using the company’s molecular testing platform that utilizes gene expression of normal epithelial cells in the respiratory tract, the BronchoGen test detects signs of lung cancer.
Allegro Diagnostics research, development and technical operations senior vice president and the study director Duncan Whitney said the goal for the company’s first clinical trial analysis is to show higher negative predictive value in lung cancer diagnoses using BronchoGen.
"We are eager to present our data that was obtained using RT-PCR at CHEST in October," Whitney added.
"We plan to use the PCR platform for routine clinical testing in the next year."